GlassScriptPhysician profile
Eloy Roman
NPI 1811018765
$66,086.09
in general payments reported to CMS, 2019-2025
78 companies · $4,669 in 2025
The $4,669 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $5,142 · 2021: $6,653 · 2022: $13K · 2023: $5,172 · 2024: $12K · 2025: $4,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,225 · Education: $527 · Travel and Lodging: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,151.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,225.00 |
| Education | $527.06 |
| Travel and Lodging | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22,603.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,666.84 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Alexion Pharmaceuticals, INC. | $4,711.89 | 2019-2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $4,087.16 | 2021-2024 | Empaveli |
| Pfizer INC. | $2,663.21 | 2019-2025 | |
| Swedish Orphan Biovitrum Ab | $2,310.00 | 2022 | |
| Merck Sharp & Dohme LLC | $2,271.31 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $2,075.59 | 2019-2025 | Erleada, Imbruvica, Darzalex |
| Celgene Corporation | $1,982.76 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $1,773.86 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $1,539.43 | 2019-2025 | |
| Incyte Corporation | $1,383.36 | 2019-2024 | Jakafi |
| Genzyme Corporation | $1,013.00 | 2019-2025 | |
| Eisai INC. | $939.97 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $721.40 | 2020-2023 | Monoferric |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $677.53 | 2019-2025 | Xtandi, Padcev, Xospata |
| Abbvie INC. | $675.74 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $598.27 | 2020-2025 | Zejula, Jemperli |
| Beigene USA, INC. | $543.15 | 2020-2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $502.09 | 2023-2025 | Orgovyx |
| Emd Serono, INC. | $478.07 | 2019-2025 | Bavencio |
| Lilly USA, LLC | $457.03 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $456.65 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $443.20 | 2019-2025 | Gavreto, Tavalisse, Rezlidhia |
| Genentech USA, INC. | $427.96 | 2019-2025 | Venclexta, Tecentriq, Tecentriq Hybreza |
| Array Biopharma INC | $384.09 | 2019-2025 | Braftovi, Mektovi, Xalkori |
| Regeneron Healthcare Solutions, INC. | $270.26 | 2019-2025 | Libtayo, Lynozyfic |
| Myovant Sciences INC. | $257.12 | 2021-2022 | |
| Seagen INC. | $254.50 | 2019-2023 | Tukysa, Padcev |
| Gilead Sciences, INC. | $238.45 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $237.97 | 2020-2025 | Ninlaro, Iclusig, Alunbrig |
| Kite Pharma, INC. | $236.18 | 2020-2023 | Yescarta |
| Exelixis INC. | $235.59 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $213.65 | 2022-2025 | Enhertu, Datroway |
| Amgen INC. | $208.75 | 2019-2022 | |
| Stemline Therapeutics INC. | $183.40 | 2023-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $175.27 | 2023-2024 | Myrisk |
| Jazz Pharmaceuticals INC. | $163.80 | 2021-2024 | Zepzelca |
| Sobi, INC | $157.40 | 2023-2025 | |
| Springworks Therapeutics, INC. | $149.74 | 2024-2025 | Ogsiveo |
| Taiho Oncology, INC. | $142.90 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $135.96 | 2021 | |
| Adc Therapeutics America, INC. | $115.04 | 2022-2023 | |
| Verastem, INC. | $99.86 | 2019-2020 | |
| Epizyme, INC. | $98.32 | 2021-2022 | |
| Beone Medicines USA, INC. | $96.15 | 2025 | Brukinsa, Tevimbra |
| Geron Corporation | $94.57 | 2024-2025 | Rytelo |
| Dova Pharmaceuticals | $92.10 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $85.68 | 2019-2024 | Onivyde |
| Tesaro, INC. | $83.30 | 2019 | |
| Mirati Therapeutics, INC. | $78.44 | 2023 | Krazati |
| Teva Pharmaceuticals USA, INC. | $65.64 | 2019-2020 | |
| Clovis Oncology, INC. | $63.38 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $54.06 | 2019 | |
| Morphosys, US INC. | $42.02 | 2023 | Monjuvi |
| Janssen Pharmaceuticals, INC | $39.82 | 2019-2020 | |
| Advanced Accelerator Applications | $32.35 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $32.10 | 2021-2022 | |
| Tempus Ai, INC | $24.46 | 2024 | Xt Cdx |
| Servier Pharmaceuticals LLC | $23.78 | 2024 | |
| G1 Therapeutics, INC. | $21.33 | 2022 | |
| Puma Biotechnology, INC. | $20.69 | 2024 | |
| Shire North American Group INC | $20.04 | 2019 | |
| Coherus Oncology, INC. | $19.07 | 2021 | |
| Novocure INC. | $17.73 | 2025 | Optune Lua (Novottf-200t) |
| Acceleron Pharma, INC. | $17.71 | 2021 | |
| Aveo Pharmaceuticals, INC. | $17.07 | 2023 | Fotivda |
| Karyopharm Therapeutics INC. | $16.12 | 2021 | |
| Blue Earth Diagnostics | $14.59 | 2022 | |
| Eusa Pharma (US) LLC | $13.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.17 | 2019 | |
| Shield Therapeutics INC | $13.08 | 2023 | |
| Cti Biopharma Corp. | $12.53 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eloy Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.